 |
|
Promising early evidence of the superior benefits of drug therapy for diabetic eye disease
April 30, 2008A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.
These findings, representing the six-month end-point evaluation of the READ-2 clinical trial coordinated by The Johns Hopkins University, were presented Monday at the 2008 Annual Meeting of The Association for Research in Vision and Ophthalmology, in Fort Lauderdale, Florida.
According to Barbara Araneo, Ph.D., director of the complications program at JDRF, "These are very encouraging results, showing that drugs we have been testing in human clinical trials can be effective in slowing or stopping the effects of eye disease brought on by diabetes."
The multi-center READ-2 Study (Ranibizumab for Edema of the mAcula in Diabetes), which began in December 2006, was designed to test the long-term safety and effectiveness of injections of the drug ranibizumab in patients with diabetic macular edema, a condition characterized by swelling of the central portion of the retina, or macula, at the back of the eye. In addition, the trial sought to determine the comparative efficacy of ranibizumab versus conventional treatment - laser photocoagulation therapy - or both together.
Macular edema, one of the most common causes of blindness, occurs when fluid and protein deposits collect on or under the macula, causing it to thicken and swell.
Participating in the clinical trial were 126 diabetic patients (average age 62) with documented Diabetic Macular Edema prior to enrollment; the majority had 20/80 vision in the eye that was treated. Patients were randomly assigned to receive one of three interventions: ranibizumab, laser photocoagulation, or a combination of the two treatments. At each visit over the course of the six-month treatment period, patients were evaluated for vision, retinal thickening, and general eye health. Although the study ended at six months, patients will be monitored for two years.
Patients treated with ranibizumab experienced significantly greater improvements in visual acuity, or clarity of vision, compared with patients receiving either of the other interventions. On average, the vision of ranibizumab-treated patients improved to 20/63 at month six, compared with essentially unchanged acuity scores of about 20/80 in both the laser and the combination treatment groups.
In addition, patients treated with ranibizumab had a 56 percent reduction in excess retinal thickness, whereas only an 11 percent reduction was seen in those receiving laser treatments.
Juvenile Diabetes Research Foundation International
The multi-center READ-2 Study (Ranibizumab for Edema of the mAcula in Diabetes), which began in December 2006, was designed to test the long-term safety and effectiveness of injections of the drug ranibizumab in patients with diabetic macular edema, a condition characterized by swelling of the central portion of the retina, or macula, at the back of the eye. In addition, the trial sought to determine the comparative efficacy of ranibizumab versus conventional treatment - laser photocoagulation therapy - or both together.
Macular edema, one of the most common causes of blindness, occurs when fluid and protein deposits collect on or under the macula, causing it to thicken and swell.
Participating in the clinical trial were 126 diabetic patients (average age 62) with documented Diabetic Macular Edema prior to enrollment; the majority had 20/80 vision in the eye that was treated. Patients were randomly assigned to receive one of three interventions: ranibizumab, laser photocoagulation, or a combination of the two treatments. At each visit over the course of the six-month treatment period, patients were evaluated for vision, retinal thickening, and general eye health. Although the study ended at six months, patients will be monitored for two years.
Patients treated with ranibizumab experienced significantly greater improvements in visual acuity, or clarity of vision, compared with patients receiving either of the other interventions. On average, the vision of ranibizumab-treated patients improved to 20/63 at month six, compared with essentially unchanged acuity scores of about 20/80 in both the laser and the combination treatment groups.
In addition, patients treated with ranibizumab had a 56 percent reduction in excess retinal thickness, whereas only an 11 percent reduction was seen in those receiving laser treatments.
Juvenile Diabetes Research Foundation International
Eye Disease News and Current Eye Disease Events RSSCognitive problems associated with diabetes duration and severity
Individuals with mild cognitive impairment appear more likely to have earlier onset, longer duration and greater severity of diabetes, according to a report in the August issue of Archives of Neurology, one of the JAMA/Archives journals.
Hyperactive immune resistance brings blindness in old age
Age-dependent macular degeneration (AMD) is the commonest cause of blindness in the western industrialised nations. Hereditary changes in the regulation of the immune system influence the risk of contracting AMD.
Study shows pine bark naturally reduces cardiovascular risk factors in diabetics
A new study published in the May 2008 (volume 8, issue 25) edition of the journal of Nutrition Research shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, reduces blood sugar in type II diabetes patients, allows people to lower their antihypertensive medication and improves cardiovascular disease (CVD) risk factors.
Hormone use related to lower risk of macular degeneration in postmenopausal women
Women who take postmenopausal hormones appear to have a lower risk of developing advanced stages of the eye disease age-related macular degeneration, especially if they had also taken oral contraceptives in the past, according to a report in the April issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
UK physician revolutionizes gene research
A dramatic new study published in the most recent issue of Nature questions some of the mechanisms underlying a new class of drugs based on Nobel Prize-winning work designed to fight diseases ranging from macular degeneration to diabetes.
Iowa State University researcher identifies eye disease in canines
Sinisa Grozdanic, assistant professor of veterinary medicine at Iowa State University, has identified and named an eye disease not previously known. The disease, Immune-Mediated Retinopathy, or IMR, causes loss of function in retinal cells and, in some cases, blindness in canines.
'Fluorescent' cells give early warning for eye disease
Scientists at the University of Michigan have shown that their new metabolic imaging instrument can accurately detect eye disease at a very early stage.
AMD discovery: New hope for treatment of vision loss
Scientists have won a major battle in the fight against age-related macular degeneration, or AMD, a blinding eye disease that affects millions of people. An international team, led by researchers at Sainte-Justine Hospital and the Université de Montréal, has identified the deficient receptor that causes the dry form of AMD.
Older whites more likely to have signs of future eye disease than blacks
White individuals older than 65 are more likely than black individuals to have characteristics that indicate they will develop more advanced forms of the eye disease age-related macular degeneration (AMD).
Team finds an economical way to boost the vitamin A content of maize
A team of plant geneticists and crop scientists has pioneered an economical approach to the selective breeding of maize that can boost levels of provitamin A, the precursors that are converted to vitamin A upon consumption.
More Eye Disease News Articles
 | The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease (Rhee, The Wills Eye Manual) Now in full color and completely updated, the Fifth Edition of this best-selling manual is a reliable quick-reference guide for all clinicians who treat eye disorders. Every disorder encountered in the office, emergency room, or hospital is covered in concise outline format: symptoms, signs, work-up, treatment, and follow-up. Also included are chapters on differential diagnosis of ocular symptoms... |
 | The Ophthalmic Assistant: A Text for Allied and Associated Ophthalmic Personnel by Harold A. Stein, Raymond M. Stein Simply written and well illustrated, this New Edition provides all the practical information ophthalmic and optometric assistants and technicians need to complete their day-to-day tasks, including paramedical training, ophthalmic technology, and efficient ophthalmic office management. It also serves as a useful guide for ophthalmic practice, featuring up-to-date coverage of ophthalmic diseases,... |
 | The Dry Eye Remedy: The Complete Guide to Restoring the Health and Beauty of Your Eyes by Robert Latkany IMPROVE YOUR VISION, REDUCE WRINKLES AND REDNESS, AND RESTORE OVERALL EYE HEALTHIt can happen any time. Your eyes feel tired. You rub them. You look at yourself in the mirror and see lines, wrinkles, bags, redness that were never there before. Dry eye often starts as a minor irritation but can develop into a deeper problem affecting your vision and appearance.Approximately 77 million Americans... |
 | Atlas of Primary Eyecare Procedures by Linda Casser, Murray Fingeret This clearly illustrated atlas offers straightforward, step-by-step descriptions of common eye procedures used regularly in primary... |
 | Reversing Dry Eye Syndrome: Practical Ways to Improve Your Comfort, Vision, and Appearance (Yale University Press Health & Wellness) by Steven L. Maskin M.D. This clear, accessible book combines detailed medical information with expert treatment advice for the estimated twenty million Americans who suffer from dry eye syndrome. Dr. Steven L. Maskin, an ophthalmologist who has been caring for dry eye patients for more than fifteen years, explains exactly what the syndrome is, why it occurs, and how it can best be managed and treated. He dispels the... |
 | Visions of Health : Understanding Iridology by Bernard Jensen |
 | Healing Your Eyes with Chinese Medicine: Acupuncture, Acupressure, & Chinese Herbs by Andy Rosenfarb For the past ten years, Andy Rosenfarb has successfully used acupuncture and Chinese medicine to treat a wide range of eye conditions. His treatments include moxibustion techniques, tuina (massage), microcurrent stimulation, Chinese herbs, and qigong exercises, along with “essential acupuncture” where essential oils are placed on acupuncture points. The culmination of his... |
 | The First Year: Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed by Daniel L. Roberts Age-related macular degeneration (AMD) is a progressive disease of the retina that develops when the light-sensing cells in the central area of vision (the macula) stop working and eventually die. Thought to be caused by a combination of genetic and environmental factors, the disease is the leading cause of blindness in people over 50. In 1995, Dan Roberts retired from teaching to help others who... |
 | The Eye Care Revolution: Prevent and Reverse Common Vision Problems by Robert Abel |
 | Searching Eyes: Privacy, the State, and Disease Surveillance in America (California/Milbank Books on Health and the Public) by Amy L. Fairchild, Ronald Bayer, James Colgrove This is the first history of public health surveillance in the United States to span more than a century of conflict and controversy. The practice of reporting the names of those with disease to health authorities inevitably poses questions about the interplay between the imperative to control threats to the public's health and legal and ethical concerns about privacy. Authors Amy L. Fairchild,... |
| © 2008 BrightSurf.com |